

ADVANCED COURSE PROGRAMME

Cancer Vaccines and Cellular Immunotherapy

**ESMO VIRTUAL
ADVANCED COURSE**

**ONLINE
29-30 APRIL 2022**

Chairs:

Andrew Furness, United Kingdom
Pedro Romero, Switzerland

ESMO Virtual Advanced Course on Cancer Vaccines and Cellular Immunotherapy

29-30 April 2022

CO-CHAIRS: Andrew Furness, United Kingdom
Pedro Romero, Switzerland

SPEAKERS: Marco Donia, Denmark
Tobias Feuchtinger, Germany
Johanna Joyce, Switzerland
Mark Middleton, United Kingdom
Emma Nicholson, United Kingdom
Michael Nishimura, United States
Pamela Ohashi, Canada
Patrick Ott, United States
Antoni Ribas, United States
Claire Roddie, United Kingdom
Juliane Walz, Germany

LEARNING OBJECTIVES

- To acquire insights in the preclinical and clinical development of vaccines and cellular immunotherapeutic approaches against cancer
- To learn about advances and ongoing research in optimal combinations of immunotherapeutic approaches involving vaccines and cell effectors, along with prognostic and predictive biomarkers
- To obtain in-depth understanding of perspectives, bottlenecks, and unmet needs in the evolving field of cancer vaccines and cellular immunotherapies

ACCREDITATION

The programme of this event has been accredited with **7 ESMO-MORA category 1 points**.

Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](https://www.esmo.org).

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org



Programme timings are to be considered CEST (Central European Summer Time)

Friday, 29 April 2022

15:00 – 15:10 10'	Welcome and course overview Andrew Furness, UK and Pedro Romero, CH
15:10 – 16:25	Session 1 – Insights and ongoing research in the understanding of anti tumour immune response: effectors, modulators, microenvironment, and tumour evasion
20'	Challenges of the tumour microenvironment Johanna Joyce, CH
20'	Adaptive immunity Pamela Ohashi, CA
20'	Immune evasion Antoni Ribas, US
15'	Discussion Faculty
16:25 – 16:40	<i>Virtual break</i>
16:40 – 17:55	Session 2 – Therapeutic strategies based on cellular effectors of anti tumour immune response
20'	Tumour infiltrating lymphocyte therapy Andrew Furness, UK
20'	T-cell receptor therapy Tobias Feuchtinger, DE
20'	CAR-T cell therapy Claire Roddie, UK
15'	Discussion Faculty
17:55 – 19:10	Session 3 – Preclinical and clinical development of cancer vaccines
20'	Preclinical development of cancer vaccines Pedro Romero, CH
20'	Clinical development of personalised cancer vaccines Patrick Ott, US
20'	Combination of cancer vaccines with other immunotherapies Juliane Walz, DE
15'	Discussion Faculty

Saturday, 30 April 2022

- 15:00 – 18:15 **Workshops sessions**
10' Introduction based on clinical cases presented by speakers
20' Discussion for each clinical case
- 15:00 – 16:00 **Workshop 1 – Cancer vaccines**
60' - Synthetic peptides – Patrick Ott, US
 - Recombinant vectors – Mark Middleton, UK
- 16:00 – 16:15 *Virtual break*
- 16:15 – 17:45 **Workshop 2 – Cell therapy**
90' - TIL therapy – Marco Donia, DK
 - TCR – Michael Nishimura, US
 - CAR-T – Emma Nicholson, UK
- 17:45 – 18:15 **Panel discussion**
30' Faculty
- 18:15 – 18:30 **Synthesis and wrap-up**
15' Andrew Furness, UK